Medincell SA (MEDCL) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.465x

Based on the latest financial reports, Medincell SA (MEDCL) has a cash flow conversion efficiency ratio of 0.465x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-14.25 Million ≈ $-16.66 Million USD) by net assets (€-30.63 Million ≈ $-35.81 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Medincell SA (MEDCL) balance sheet quality index to measure how much of total assets are equity-financed.

Medincell SA - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Medincell SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check MEDCL cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Medincell SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Medincell SA ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
China High-Speed Railway Technology SHE:000008	0.015x
Dazhong Transportation Group Co Ltd A SHG:600611	0.028x
Dongguan Tarry Electronics Co.Ltd SHE:300976	0.018x
Beijing Watertek Information Technology Co Ltd SHE:300324	0.004x
Intelbras S.A. - Indústria de Telecomunicação Eletrônica Brasileira SA:INTB3	0.150x
Chengdu Yunda Technology Co Ltd SHE:300440	0.004x
Guizhou Bailing Group Pharmaceutical Co Ltd SHE:002424	0.092x
Shanghai Cooltech Power Co Ltd SHE:300153	0.040x

Annual Cash Flow Conversion Efficiency for Medincell SA (2016–2025)

The table below shows the annual cash flow conversion efficiency of Medincell SA from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see MEDCL market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-03-31	€-16.37 Million ≈ $-19.13 Million	€19.46 Million ≈ $22.76 Million	-1.189x	-507.24%
2024-03-31	€-40.82 Million ≈ $-47.73 Million	€-11.92 Million ≈ $-13.94 Million	0.292x	-41.20%
2023-03-31	€-42.29 Million ≈ $-49.45 Million	€-21.00 Million ≈ $-24.56 Million	0.497x	-68.91%
2022-03-31	€-13.37 Million ≈ $-15.63 Million	€-21.36 Million ≈ $-24.97 Million	1.598x	+217.37%
2021-03-31	€8.92 Million ≈ $10.42 Million	€-12.14 Million ≈ $-14.19 Million	-1.361x	-273.23%
2020-03-31	€-15.96 Million ≈ $-18.66 Million	€-12.54 Million ≈ $-14.66 Million	0.786x	+130.79%
2019-03-31	€6.24 Million ≈ $7.30 Million	€-15.93 Million ≈ $-18.63 Million	-2.552x	-652.58%
2018-03-31	€-11.75 Million ≈ $-13.74 Million	€-5.43 Million ≈ $-6.34 Million	0.462x	-68.86%
2017-03-31	€-2.29 Million ≈ $-2.67 Million	€-3.39 Million ≈ $-3.97 Million	1.483x	+2787.40%
2016-03-31	€1.32 Million ≈ $1.55 Million	€68.00K ≈ $79.50K	0.051x	--

About Medincell SA

PA:MEDCL France Biotechnology

Market Cap

$1.09 Billion

€931.42 Million EUR

Market Cap Rank

#9014 Global

#146 in France

Share Price

€25.94

Change (1 day)

-1.44%

52-Week Range

€15.70 - €38.46

All Time High

€38.46